Calliditas • Stockholm • Full time
Position Summary
The Vice President, Head of Pharmacovigilance oversees all adverse event management, safety surveillance and signal detection practices for Calliditas’ portfolio of development and marketed products, and leads the management of all collaborative, partner and contract research organisation relationships (with respect to pharmacovigilance).
The Vice President, Head of Pharmacovigilance must have executive presence, excellent people management skills, advanced safety data review/analysis experience, superb written and verbal communication skills, as well as hands-on pharmacovigilance experience with a proven track record of significant accomplishment.
The Vice President, Head of Pharmacovigilance will report to the Chief Medical Officer (CMO) and be a part of the Clinical Team. The position will be placed at Calliditas headquarter in central Stockholm.
Tasks and responsibilities/accountabilities:
Competence requirements for the position (education and experience)
Reasons to join the Calliditas Team
All applications are handled by Life Science Medics
Life Science Medics have been retained on this project and working exclusively with Calliditas to lead the recruitment process for this role. We kindly request that other external recruitment companies refrain from contacting Life Science Medics and Calliditas about this job posting.
Please note as part of our recruitment process, you will be expected to complete a written questionnaire exploring aspects of your background and to have an in-depth interview with a representative of Life Science Medics prior to the confirmation of your candidacy. To apply for this position or have an initial confidential discussion please reach out to Rebecca Bray, Director at Life Science Medics.
+44 (0) 208 124 4956
Life Science Medics Ltd, Global Executive Search Leaders for MDs in the Life Science Industry
About Us
Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas’ lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO®, conditional marketing authorization by the European Commission under the trade name KINPEYGO® and by China’s National Medical Products Administration (NMPA) Nefecon®. TARPEYO, KINPEYGO® and Nefecon® are the first and only treatments approved for IgA nephropathy.
Calliditas also has a pipeline in orphan-focused indications. Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib.
Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
Calliditas består av ett kreativt team av forskare, kliniker, och andra ämnesexperter som med medkänsla engagerar sig för personer med sällsynta sjukdomar som står inför höga medicinska behov. Vår framgång som företag beror på vår förmåga att fungera som ett enat team, och vi är fast beslutna att tillhandahålla en säker, stimulerande och uppmuntrande miljö där varje anställd ges möjlighet att blomstra och bidra till vårt uppdrag.
For this position, the company has chosen to use an external application process. This means that you must apply on their site directly and cannot apply via Uptrail.